Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
11 oct. 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya to Participate at Four Upcoming Investor Conferences
31 août 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming...
Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
08 août 2022 16h05 HE
|
Akoya Biosciences, Inc.
Q2 2022 revenue $17.9 million, 37% y/y growthRaising FY 2022 revenue guidance range to $71-74 million MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA)...
Akoya to Participate at Two Upcoming Investor Conferences
27 juil. 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming...
Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022
12 juil. 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28 juin 2022 08h05 HE
|
Akoya Biosciences, Inc.
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...
Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting
01 juin 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, will present for the first time, data generated using its proprietary RNA...
Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
05 mai 2022 16h05 HE
|
Akoya Biosciences, Inc.
Q1 2022 revenue $16.9 million, 38% growth over prior year periodRaising FY 2022 revenue guidance range to $70-73 million MARLBOROUGH, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences,...
Akoya to Participate at Three Upcoming Investor Conferences
03 mai 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming...
Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer
19 avr. 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company’s...